TEXT OF STORY
STEVE CHIOTAKIS: French pharmaceutical drug giant Sanofi-Aventis says it wants to buy the American drug company Genzyme for more than $18 billion. The French are turning up the pressure for the deal, after the Americans rejected a smaller offer earlier this summer.
More from Berlin, and reporter Kyle James.
KYLE JAMES: Genzyme is the world’s largest maker of medicines for genetic diseases, but has been hit by production problems over the last few years. Still, it’s got two potential blockbuster drugs in the pipeline — one for multiple sclerosis, another for cholesterol. And that makes Genzyme a very attractive candidate to Sanofi.
For one, big drug makers are increasingly looking towards biotech companies for future growth. And another reason is the French drug maker will soon lose a lot of revenue.
OLIVER RAKAU: Many pharmaceuticals are losing their patents on the big blockbusters.
Oliver Rakau is an analyst with Deutsche Bank research. He says Sanofi is now facing generic competition on two of its best-selling drugs.
RAKAU: Therefore they need acquisitions often of small, innovative companies in order to increase their sales again.
While Sanofi’s announcement falls short of a hostile bid, media reports say the company might take its offer directly to shareholders. The recent uptick in mergers and acquisitions is especially acute in the pharmaceutical field. Rakau says companies can’t just hire more scientists, but need to join up with firms that have research teams and projects already in place.
In Berlin, I’m Kyle James for Marketplace.
Marketplace is on a mission.
We believe Main Street matters as much as Wall Street, economic news is made relevant and real through human stories, and a touch of humor helps enliven topics you might typically find…well, dull.
Through the signature style that only Marketplace can deliver, we’re on a mission to raise the economic intelligence of the country—but we don’t do it alone. We count on listeners and readers like you to keep this public service free and accessible to all. Will you become a partner in our mission today?